Today, the World Health Organization issued and emergency use listing (EUL) for NVX-CoV2373, expanding the basket of WHO-validated vaccines against the SARS-CoV-2 virus.
The vaccine, named CovovaxTM, is produced by the Serum Institute of India under licence from Novavax and is part of the COVAX facility portfolio, giving a much-needed boost to ongoing efforts to vaccinate more people in lower-income countries.
WHO’s EUL procedureassesses the quality, safety and efficacy of COVID-19 vaccines and is a prerequisite for COVAX vaccine supply.
It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines. “Even with new variants emerging, vaccines remain one of the most effective tools to protect